Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCT2080220503
JPRN-jRCT2080220503UnknownPhase 2

TK-FT Phase 2 Study (Efficacy and Safety Study)

TEIKOKU SEIYAKU CO., LTD.0 sites50 target enrollmentStarted: January 15, 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Enrollment
50
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to <= 74age old (—)
Sex
All

Inclusion Criteria

  • •1)Patients who were diagnosed with cancer
  • •2)Patients who are 20-74 years old at the time of informed consent
  • •3)Patients who are managed with opioid maintenance therapy for persistent cancer pain
  • •4)Patients who are managed with rescue opioid for breakthrough cancer pain

Exclusion Criteria

  • •1)Patients with uncontrolled or rapidly increasing cancer pain
  • •2)Patients with organic encephalopathies such as intracranial hypertension, consciousness disturbed, coma or brain tumour
  • •3)Patients with history of convulsive seizure
  • •4)Patients with asthma

Investigators

Similar Trials

Active, not recruiting
Phase 1
A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC)Relapsed/Refractory Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2021-002566-40-NLAmgen Inc.220
Recruiting
Phase 2
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301)lung cancerSmall Cell Lung Cancer
NL-OMON54228Amgen3
Active, not recruiting
Phase 1
A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC)
EUCTR2021-002566-40-ATAmgen Inc.160
Active, not recruiting
Phase 1
A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC)Relapsed/Refractory Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2021-002566-40-GRAmgen Inc.160
Active, not recruiting
Phase 1
A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC)Relapsed/Refractory Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2021-002566-40-PLAmgen Inc.160